drugset / Trial / NCT01042366
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
Phase 2
Terminated
16 enrolled
John Kirkwood
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine what effect using an experimental tumor vaccine (a substance or group of substances meant to cause the immune system to respond to a tumor) made using patients' own tumor cells and blood cells will have on their melanoma.
Timeline
- Start
- 2002-10
- Primary completion
- 2014-11
- Completion
- 2014-11
Outcome
Outcome not reported
Stopped (Enrollment): “Closed to accrual in March 2009 for slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vaccination | Vaccine | 1e+06 cells | Other |
| Subject | Vaccination | Vaccine | 5e+06 cells | Other |